目的 探討六味地黃丸聯(lián)合唑來膦酸治療婦女絕經(jīng)后骨質(zhì)疏松的臨床效果。方法 選取2015年6月—2017年1月廣東醫(yī)科大學(xué)附屬醫(yī)院收治的86例絕經(jīng)后骨質(zhì)疏松患者，隨機(jī)分為對照組和治療組，每組各43例。對照組靜脈滴注唑來膦酸注射液，5 mg/次，1次/年。治療組在此基礎(chǔ)上口服六味地黃丸，8丸/次，3次/d。所有患者均連續(xù)治療12個(gè)月。觀察兩組的臨床療效，比較兩組治療前后視覺模擬（VAS）評分、簡明健康狀況調(diào)查量表（SF-36）評分、腰椎1～4骨質(zhì)密度（BMD）、全髖關(guān)節(jié)骨BMD、左側(cè)股骨頸BMD、Ⅰ型原膠原氨基端前肽（PINP）、β-膠原降解產(chǎn)物（β-CTX）、堿性磷酸酶（ALP）、骨鈣素（BGP）的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為79.07%、95.35%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組VAS評分、血清PINP、β-CTX、ALP及BGP水平顯著降低，SF-36評分、腰椎1～4 BMD值、全髖關(guān)節(jié)骨BMD值、左側(cè)股骨頸BMD值顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組VAS評分、血清PINP、β-CTX、ALP及BGP水平低于對照組，SF-36評分、腰椎1～4 BMD值、全髖關(guān)節(jié)骨BMD值、左側(cè)股骨頸BMD值高于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 六味地黃丸聯(lián)合唑來膦酸治療婦女絕經(jīng)后骨質(zhì)疏松具有較好的臨床療效，可有效緩解患者疼痛癥狀，增加骨密度，提高生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effects of Liuwei Dihuang Pills combined with zoledronic acid in treatment of postmenopausal osteoporosis in women. Methods Patients (86 cases) with postmenopausal osteoporosis in Affiliated Hospital of Guangdong Medical University from June 2015 to January 2017 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were iv administered with Zoledronic Acid Injection, 5 mg/time, once yearly. Patients in the treatment group were po administered with Liuwei Dihuang Pills on the basis of the control group, 8 pills/time, three times daily. Patients in two groups were treated for 12 months. After treatment, the clinical efficacy was evaluated, and the VAS score, SF-36 score, lumbar vertebrae 1~4 BMD, total hip bone BMD, left femoral neck BMD, PINP, β-CTX, ALP, and BGP in two groups before and after treatment. Results After treatment, the clinical efficacy in the control and treatment groups were 79.07% and 95.35%, and there were differences between two groups (P < 0.05). After treatment, VAS score, PINP, β-CTX, ALP, and BGP in two groups were significantly decreased, but SF-36 score, lumbar vertebrae 1~4 BMD, total hip bone BMD, left femoral neck BMD were significantly increased, and there were differences in the same group (P < 0.05). After treatment, VAS score, PINP, β-CTX, ALP, and BGP in the treatment group were lower than those in the control group, but SF-36 score, lumbar vertebrae 1~4 BMD, total hip bone BMD, left femoral neck BMD were higher than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Liuwei Dihuang Pills combined with zoledronic acid has significant clinical effect in treatment of postmenopausal osteoporosis in women, and can effectively relieve pain symptoms, also can increase bone density and improve life quality, which has a certain clinical application value.